Clinical trials
Cancer Risk clinical trials
Below are recruiting cancer risk clinical trials, each written for real people, not researchers. We’re tracking 717 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06852014Recruiting
Nutritional supplement study for malnourished pancreatic cancer patients
This trial tests whether a special drink called Peptamen 1.6 can help improve nutrition and recovery in patients who are malnourished or at risk and have had surgery for pancreatic cancer. It aims to understand how the supplement affects the body right after surgery.
Málaga, MálagaAges 18 years+ - NCT07095517RecruitingPhase 1
Preventing early-onset colorectal tumors with tirzepatide
This study tests if tirzepatide can help prevent early-onset colorectal tumors in people aged 18-50 who have had certain types of polyps removed. It aims to find risk factors and ways to stop colorectal cancer before it starts.
Boston, MassachusettsAges 18–50 - NCT07321197Recruiting
Kidney removal with or without lymph node removal for high risk kidney cancer
This study is for people with high-risk kidney cancer who are having their whole kidney removed. It compares surgery alone versus surgery plus removing lymph nodes from the tumor area to see if removing the nodes helps control the cancer better.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06358625Recruiting
Study of brain recurrence risk in HER2-positive breast cancer
This study looks at women with HER2-positive breast cancer who will get chemotherapy before surgery. The goal is to find out what factors might increase the chance of the cancer spreading to the brain later on.
RennesAges 18 years+ - NCT07140679RecruitingPhase 2
Immunotherapy after surgery for certain colon cancers
This trial tests whether the immunotherapy drug toripalimab can lower the risk of colon cancer coming back after surgery. It is for people with a specific genetic feature called mismatch repair deficiency (dMMR) in their tumor, and whose cancer was at a higher stage (stage IIB, IIC, or III).
Atlanta, GeorgiaAges 18 years+ - NCT07519837Recruiting
Understanding Cancer Wasting in Digestive Cancers
This study explores why certain cancers cause patients to lose weight and muscle (called cancer cachexia) and tests ways to reverse it. Researchers will study tissue samples from patients with cancers of the food pipe, liver, stomach, or bile ducts to understand what's happening at a cellular level.
Shenyang, LiaoningAges 18 years+ - NCT05665504Recruiting
Biomarker test for managing early lung nodules after treatment
This study looks at lung “biomarkers” (test results from your nodule/tissue) to better predict risk of cancer coming back and to guide long-term follow-up. It may help doctors choose the best surveillance plan after surgery or other treatment for early, potentially curable lung cancer.
Tampa, FloridaAges 18 years+ - NCT07288632Recruiting
Lung cancer gene test and blood clot risk study
This study looks at whether certain gene profiles in advanced lung cancer affect the risk of blood clots. It may help doctors better understand and prevent clots in people starting new cancer treatment.
Perugia, PerugiaAges 18 years+ - NCT04871542Recruiting
Predicting risk of immune therapy side effects
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Anchorage, AlaskaAges 18 years+ - NCT03848962Recruiting
Share leftover or collected samples for research
This study helps collect and share human samples (like blood or other specimens) so researchers can do new studies. It’s mainly about providing samples for research use, not testing a treatment on you.
Huntsville, AlabamaAges 1 month–89 years - NCT05366153Recruiting
Plan to lower future heart attack risk after past cancer treatment
This trial tests whether a “risk-guided” care plan can help prevent coronary artery disease (the buildup that can lead to heart attacks) in people who had cancer treatment that can affect the heart. You may get closer heart risk monitoring and guidance to reduce risk factors, such as cholesterol—especially if you can safely take statins.
Hobart, TasmaniaAges 40–70 - NCT05557578RecruitingPhase 2
New drug before surgery for resectable bile duct cancer
This Phase 2 trial tests a “neoadjuvant” (before-surgery) treatment for resectable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) that has higher risk of coming back. It aims to shrink or control the cancer before the operation, and to see if patients can safely undergo surgery afterward.
Hangzhou, ZhejiangAges 18–75 - NCT05707819Recruiting
Sintilimab plus chemoradiotherapy for high-risk nasopharyngeal cancer
This trial tests whether adding sintilimab (an immune treatment) to standard chemoradiotherapy can improve outcomes for people with high-risk, locally advanced nasopharyngeal (throat) cancer. It may help your immune system work better against the cancer alongside radiation and chemotherapy.
Nanning, GuangxiAges 18–70 - NCT06263491RecruitingPhase 2
Pirtobrutinib and Rituximab for Low/Medium Risk MCL
This trial tests a combination of two medications, pirtobrutinib and rituximab, for people newly diagnosed with low- or medium-risk mantle cell lymphoma. It aims to see if this approach is effective and safe without needing chemotherapy.
Houston, TexasAges 18 years+ - NCT06607406Recruiting
Timing of radiation after surgery for head and neck cancer
This study tests whether starting radiation therapy more than 6 weeks (but within 16 weeks) after surgery is safe and effective for people with certain high-risk head and neck cancers. It could help those who had to delay radiation for recovery or other reasons.
Charlotte, North CarolinaAges 18 years+ - NCT07187726Recruiting
Trial to predict arm swelling risk during breast cancer radiation
This trial checks if telling you about your personal risk of arm swelling (based on a computer prediction) helps prevent it. You'll wear a compression sleeve during radiation and be monitored closely.
ArrasAges 18 years+ - NCT07680699Recruiting
Early immunotherapy for high-risk stage II melanoma
This trial tests early anti-PD-1 therapy for people with stage IIB or IIC melanoma, or stage III (N1c). It aims to see if starting treatment sooner helps prevent the cancer from coming back.
São Paulo, São PauloAges 18 years+ - NCT06246149RecruitingPhase 3
Tebentafusp after treatment for high-risk eye melanoma
This trial tests a new drug called tebentafusp given after standard treatment (surgery or radiation) for high-risk uveal melanoma that hasn't spread. The goal is to see if it helps prevent the cancer from coming back.
Lake Success, New YorkAges 18 years+ - NCT07298577Enrolling by invitation
Using blood test and ultrasound to find early liver cancer in Asia
This study tests whether adding a simple blood test (GAAD score) to a routine liver ultrasound can find early-stage liver cancer sooner in people with chronic liver conditions. It aims to improve detection in Asian populations at risk.
Bangkok Noi, BangkokAges 18 years+ - NCT07061769Enrolling by invitation
Using a gentle head device to help with nerve pain from chemo
This trial tests a low-intensity cranial PEMF device to see if it can reduce nerve pain caused by chemotherapy. Participants use the device at home and receive text messages to track their symptoms.
Newport Beach, CaliforniaAges 18–60 - NCT07449208Recruiting
Esophagectomy leak risk registry study
This study follows people having surgery to remove part of the esophagus (esophagectomy) who are at higher risk for a leak where the esophagus is reconnected. The goal is to learn more about who develops leaks and how to prevent them.
Basking Ridge, New JerseyAges 18 years+ - NCT06047977RecruitingPhase 1
Immune cell therapy for high-risk solid tumors in children and young adults
This trial uses a patient's own tumor-fighting immune cells (TILs) to treat high-risk solid tumors outside the brain in children and young adults. It has two parts: first, a tumor sample is collected during surgery, and then the immune cells are grown in a lab and given back to the patient to attack the cancer.
St. Petersburg, FloridaAges 1–21 - NCT07346092Recruiting
Health beliefs and social behaviors about nicotine pouches
This study looks at how graduate students at Ohio State University perceive and use oral nicotine pouches. The goal is to create better ways to communicate the addictive risks of these products.
Columbus, OhioAges 21 years+ - NCT04476485Recruiting
Predicting breast cancer recurrence after extended hormone therapy
This trial looks at factors that may predict whether hormone receptor–positive breast cancer will come back after you’ve already completed 5 years of hormone (endocrine) therapy. It may help identify who benefits most from longer treatment and follow-up.
Harbin, HeilongjiangAges 18–70
Hear when a new Cancer Risk trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cancer risk?
- Yes. Clin2 currently lists 717 recruiting cancer risk studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cancer risk trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cancer risk trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.